Trending Stocks: Titan International Inc. (NYSE:TWI), Gigamon Inc. (NYSE:GIMO), Mizuho Financial Group, Inc. (NYSE:MFG), Team Health Holdings, Inc. (NYSE:TMH),

Titan International Inc. (NYSE:TWI) said that, it is set to issue its Q415 quarterly earnings data on Thursday, February 25th.

Titan International Inc. (NYSE:TWI) belongs to Industrial Goods sector. Its net profit margin is -9.40% and weekly performance is -11.60%. On last trading day company shares ended up at $3.81. Titan International Inc. (NYSE:TWI) distance from 50-day simple moving average (SMA50) is 11.95%.

Gigamon Inc. (NYSE:GIMO) has announced that its CEO, Paul Hooper, will be ringing the closing bell today at the New York Stock Exchange, to coincide with the launch of a major new marketing campaign.

Gigamon Inc. (NYSE:GIMO) shares advanced 6.22% in last trading session and ended the day at $26.30. GIMO Gross Margin is 79.40% and its return on assets is 2.60%. Gigamon Inc. (NYSE:GIMO) quarterly performance is -3.77%.

On 16 February, Mizuho Financial Group, Inc. (NYSE:MFG) and Cognizant have entered into a strategic agreement to develop a block-chain solution for secure record-keeping of documents among Mizuho Financial Group companies around the world.

On 24 February, Mizuho Financial Group, Inc. (NYSE:MFG) shares advanced 1.74% and was closed at $2.92. MFG EPS growth in last 5 year was 17.10%. Mizuho Financial Group, Inc. (NYSE:MFG) year to date (YTD) performance is -27.72%.

Team Health Holdings, Inc. (NYSE:TMH) announced results for its fourth quarter and full fiscal year of 2015. Net revenue increased 23.9% to $979.6 million from $790.7 million in the fourth quarter of 2014. Acquisitions contributed 19.5%, same contract revenue contributed 3.6%, and net sales growth contributed 0.8% of the increase in quarter-over-quarter growth in net revenue.

Team Health Holdings, Inc. (NYSE:TMH) ended the last trading day at $38.01. Company weekly volatility is calculated as 5.89% and price to cash ratio as 151.58. Team Health Holdings, Inc. (NYSE:TMH) showed a weekly performance of 2.04%.

Brean Capital reissued their buy rating on shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) in a report issued on Thursday, Marketbeat.com reports. Brean Capital currently has a $13.00 target price on the biotechnology company’s stock.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares remains unchanged in last trading session and ended the day at $1.86. CNAT return on assets is -57.10%. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) quarterly performance is -39.61%.

Leave a Reply

Your email address will not be published. Required fields are marked *